S&P Futures
3,816.50 -9.00 (-0.24%) Dow Futures
30,906.00 -27.00 (-0.09%) Nasdaq Futures
11,636.25 -38.00 (-0.33%) Russell 2000 Futures
1,733.90 -4.40 (-0.25%) Crude Oil
112.60 +0.84 (+0.75%) Gold
1,826.30 +5.10 (+0.28%)
TC Biopharm (Holdings) Plc (TCBP)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.3949 |
| Open | 0.4022 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 3000 |
| Day's Range | 0.3623 - 0.4089 |
| 52 Week Range | 0.3300 - 3.5000 |
| Volume | |
| Avg. Volume | 836,791 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
TC Biopharm Announces Closing of $4 Million Underwritten Public Offering
TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer indications, today announced the closing of its previously announced underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million,
- PR Newswire
TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of an underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting d
- PR Newswire
TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally
TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Acute myeloid leukemia (AML) diagnoses have risen globally according to a recent study entitled, "EPR22-104: A Comparison of the Burden of Leukemia Amongst Various Regions of the World, 1990-2019," published in the Journal of the National Comprehensive Cancer Networ
